Abstracts tagged "canakinumab"

Abstract Number: 046 • 2023 Pediatric Rheumatology Symposium
Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors
Yoel Levinsky¹, rotem tal², Liora Harel³ and Gil Amarilyo⁴, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ³Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ⁴Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: IL-1 inhibitor are approved for familial Mediterranean fever (FMF) patients who are resistant to colchicine. However, it is imperative to continue concomitant treatment with…
Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Katy shehadeh¹, Yoel Levinsky², rotem tal³, Neta Hana Aviran³, Yonatan Butbul Aviel⁴, Irit Tirosh⁵, Shelly Kagan⁶, Tarek Zoabi³, Shiri Spielman⁷, Adi Miller-Barmak⁴, Rotem Semo Oz⁸, Liora Harel⁹, Gabriel Chodick¹⁰ and Gil Amarilyo⁶, ¹Tel Aviv University, Tel Aviv, Israel, ²Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Rambam Medical center, Haifa, Israel, ⁵Sheba Medical Center, Savyon, Israel, ⁶Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Sheba Tel-HaShomer Medical Center, Givataim, Israel, ⁸Sheba medical center, Herzelyia, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Maccabitech institute for research and innovation, Maccabi healthcare services, Tel Aviv, Israel
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…
Abstract Number: 1245 • 2019 ACR/ARP Annual Meeting
Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease
Corrado Campochiaro¹, Alessandro Tomelleri ², De Luca Giacomo ³, Nicola Farina ², Elena Baldissera ², Giulio Cavalli ² and Lorenzo Dagna ², ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare auto-inflammatory condition characterized by fever, arthritis, skin rash, and multi-organ inflammation. The pathogenesis of AOSD is centrally…
Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting
Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Rina Denisova ², Tatyana Dvoryakovskaya ², Ksenia Isaeva ², Ivan Kriulin ², Alina Alshevskaya ³ and Andrey Moskalev ³, ¹National Medical Research Center of Children`s Health, Moscow, Russia, ²NMRCCH, Moscow, Russia, ³Biostatistics and Clinical Trials Center, Novosibirsk, Russia
Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…
Abstract Number: 2903 • 2019 ACR/ARP Annual Meeting
Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission
Jasmin Kuemmerle-Deschner¹, Norbert Blank ², Michael Borte ³, Ivan Foeldvari ⁴, Gerd Horneff ⁵, Prasad Thomas Oommen ⁶, Catharina Schuetz ⁷, Frank Weller-Heinemann ⁸, Julia Weber-Arden ⁹ and Tilmann Kallinich ¹⁰, ¹University Hospital Tuebingen, Pediatric Department, Tuebingen, Germany, ²Rheumatology, University Hospital Heidelberg, Germany, Heidelberg, Germany, ³3ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Duesseldorrf, Germany, ⁷Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany, Dreaden, Germany, ⁸Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ⁹Novartis Pharma GmbH Germany, Nuremberg, Germany, ¹⁰Charite, Berlin, Germany
Background/Purpose: Targeting the interleukin(IL)-1 pathway with anti-IL-1 drugs is a treatment option in patients with autoinflammatory diseases like monogenic periodic fever syndromes. The study aims…
Abstract Number: 445 • 2018 ACR/ARHP Annual Meeting
Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Matthias Schieker¹, Linda Mindeholm¹, Jens Praestgaard², Celeste Scotti¹, Daniel Solomon³, Tom Thuren⁴, Kasper Dreyer⁵, Ronenn Roubenoff¹ and Paul M. Ridker⁶, ¹Novartis Institutes for Biomedical Research, Basel, Switzerland, ²Novartis Institutes for Biomedical Research, East Hanover, NJ, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Novartis Pharma AG, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Division of Preventive Medicine, Cardiovascular Diseases, Brigham and Women's Hospital, Boston, MA
Background/Purpose: In osteoarthritis (OA), there are no therapeutics to prevent disease progression. Canakinumab, a monoclonal antibody targeting interleukin-1β, reduced inflammation and cardiovascular events in the…
Abstract Number: 1411 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry
Jasmin B. Kuemmerle-Deschner¹, Ulrich A. Walker², Hugh H. Tilson³, Philip N. Hawkins⁴, Tom van der Poll⁵, Kristina Franke⁶, Antonio Speziale⁷, Eleni Vritzali⁷ and Hal M. Hoffman⁸, ¹Pediatrics, University Hospital Tübingen, Tübingen, Germany, ²Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ³University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, ⁴University College London Medical School, London, United Kingdom, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶IQVIA, Durham, NC, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸University of California, San Diego, San Diego, CA
Background/Purpose: Canakinumab (CAN), a human anti-interleukin-1 monoclonal antibody, has shown to be efficacious and safe in the treatment of all phenotypes of cryopyrin-associated periodic syndrome…
Abstract Number: 1414 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Toni Hospach³, Ivan Foeldvari⁴, Michael Borte⁵, Frank Weller-Heinemann⁶, Kirsten Minden⁷ and Ariane Klein⁸, ¹Asklepios Kinderklinik St. Augustin GmbH, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁴Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁵St Georg Hospital, Leipzig, Germany, ⁶PRINTO, Genoa, Italy, ⁷Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologic drugs is particularly important in pediatric patients(pts). Since 2001, the German Biologics JIA Registry (BIKER) is allowing to follow up…
Abstract Number: 1418 • 2018 ACR/ARHP Annual Meeting
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
Isabelle Koné-Paut¹, Maryam Piram², Susanne Benseler³, Jasmin B. Kuemmerle-Deschner⁴, Annette F. Jansson⁵, Itzhak Rosner⁶, Alberto Tommasini⁷, Sara Murias⁸, Omer Karadag⁹, Jeremy Levy¹⁰, Serge Smeets¹¹ and Fabrizio De Benedetti¹², ¹APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ²Pediatrics, APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatrics, University Hospital Tübingen, Tübingen, Germany, ⁵Ludwig Maximilian University, Munich, Germany, ⁶Bnai-Zion Medical Center, Haifa, Israel, ⁷Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ¹⁰BIOP, Reinach, AR, Switzerland, ¹¹Novartis Pharma B.V., Arnhem, Netherlands, ¹²IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: AIDAI is a novel and unique, validated patient (pt)-reported assessment tool to evaluate disease activity in familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
Abstract Number: 368 • 2017 ACR/ARHP Annual Meeting
Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever
Kenan Barut, Amra Adrovic, Sezgin Sahin, Asli Kaplan and Ozgur Kasapcopur, Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: The colchicine-resistant FMF (crFMF) is defined as 6 or more polyserositis attacks in the last year despite the regular usage of colchicine in the…
Abstract Number: 376 • 2017 ACR/ARHP Annual Meeting
Improvement of Disease Activity in Patients with Colchicine-Resistant FMF, Hids/Mkd and TRAPS Assessed By Autoinflammatory Disease Activity Index (AIDAI): Results from a Randomized Phase III Trial
Isabelle Koné-Paut¹, Michaël Hofer², Susanne Benseler³, Jasmin B. Kuemmerle-Deschner⁴, Annette Jansson⁵, Itzhak Rosner⁶, Raffaele Manna⁷, Sara Murias⁸, Omer Karadag⁹, Lori Tucker¹⁰, Ilonka Orban¹¹, Vincent Tormey¹², Maria Alessio¹³, Huri Ozdogan¹⁴ and Fabrizio De Benedetti¹⁵, ¹Bicêtre Hospital, APHP, Univeristy Paris Sud, Paris, France, ²Unité romande d’immuno-rhumatologie pédiatrique, CHUV, University of Lausanne, Genova, Italy, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴University Hospital Tuebingen, Tuebingen, Germany, ⁵Ludwig Maximilian University, Munich, Germany, ⁶Bnai-Zion Medical Center, Haifa, Israel, ⁷Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁰BC Children's Hospital, Vancouver, BC, Canada, ¹¹Orszagos Reumatologial es Fizioterepias, Budapest, Hungary, ¹²University College Hospital Galway, Galway, Ireland, ¹³A Osped-Universit Policlinico Federico II, Univ degli Studi di Napoli, Napoli, Italy, ¹⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Division of Rheumatology, Istanbul, Turkey, ¹⁵Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy
Background/Purpose: AIDAI is a novel, validated tool for the assessment of disease activity across a wide spectrum of autoinflammatory diseases including recurrent fever syndromes such…
Abstract Number: 77 • 2017 Pediatric Rheumatology Symposium
Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard R. Lauwerys⁴, Antonio Speziale⁵, Xiaoling Wei⁶ and Ronald Laxer⁷, ¹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Unité romande d’immuno-rhumatologie pédiatrique, CHUV, University of Lausanne, Genova, Italy, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Service de rhumatologie, Pôle de pathologies rhumatismales inflammatoires et systémiques, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis, Shanghai, China, ⁷Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present the…
Abstract Number: 2378 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
Joost Frenkel¹, Jordi Anton², Avi Livneh³, Eldad Ben-Chetrit⁴, Paul Brogan⁵, Segundo Bujan-Rivas⁶, Tamás Constantin⁷, Fabrizio De Benedetti⁸, Marco Gattorno⁹, Ahmet Gül¹⁰, Hal M. Hoffman¹¹, Isabelle Kone-Paut¹², Helen Lachmann¹³, Seza Ozen¹⁴, Anna Simon¹⁵, Jeroen Van der Hilst¹⁶, Andrew Zeft¹⁷, Antonio Speziale¹⁸, Guido Junge¹⁸ and Lucy Xu¹⁹, ¹University Medical Center,Utrecht, Utrecht, Netherlands, ²Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, ³Department of Medicine F, Sheba Medical Center, Tel Hashomer, Israel, ⁴Medicine A Rheum Unit, Hadassah University Hosp, Jerusalem, Israel, ⁵Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁶Vall d'Hebron Hospital, Barcelona, Barcelona, Spain, ⁷Unit of Paediatric Rheumatology, 2nd Dpt of Pediatrics, Semmelweis University, Budapest, Hungary, ⁸Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ⁹UO Pediatria 2, Istituto Giannina Gaslini, Genova, Italy, ¹⁰Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹¹Pediatric Allergy, Immunology and Rheumatology, University of California at San Diego/Rady Children Hospital, La Jolla, CA, ¹²PRINTO, Genoa, Italy, ¹³UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁴Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶Department of infectious disease and immunity, Jessa Hospital, Hasselt, Hasselt, Belgium, ¹⁷Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ¹⁸Novartis Pharma AG, Basel, Switzerland, ¹⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: The pharmacokinetics (PK) of canakinumab (CAN) and total interleukin (IL)-1β kinetics have been well investigated in CAPS patients (pts).1 Here we present the PK…
Abstract Number: 2380 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard Lauwerys⁴, Antonio Speziale⁵, Karolynn Leon⁶, Xiaoling Wei⁷ and Ronald Laxer⁸, ¹Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Shanghai Novartis Trading Limited, Shanghai, China, ⁸The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cryopyrin-Associated Periodic Syndrome (CAPS), is a rare hereditary auto inflammatory disorder representing 3 phenotypes: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic…
Abstract Number: 3206 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Childhood Vaccinations in CAPS Patients Treated with Canakinumab: Results from an Open-Label Phase III Extension Study
Paul Brogan¹, Michaël Hofer², Jasmin B. Kuemmerle-Deschner³, Bernard Lauwerys⁴, Antonio Speziale⁵, Xiaoling Wei⁶ and Ronald Laxer⁷, ¹Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ²Pediatrie, Unité Romande de Rhumatologie Pédiatrique, Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³University Hospital Tuebingen, Tuebingen, Germany, ⁴Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Shanghai Novartis Trading Limited, Shanghai, China, ⁷Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Canakinumab (CAN) has been shown not to impair antibody production following vaccination in children in an open-label phase 3 study (NCT01302860).1 Here we present…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].